Mineralys Therapeutics (NASDAQ:MLYS) Releases Earnings Results, Misses Estimates By $0.30 EPS

Mineralys Therapeutics (NASDAQ:MLYS) released its earnings results on Monday. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.30), Zacks reports. During the same quarter in the previous year, the firm posted ($0.57) EPS.

Mineralys Therapeutics Price Performance

Shares of NASDAQ:MLYS traded down $1.54 during midday trading on Tuesday, reaching $13.38. The company had a trading volume of 397,621 shares, compared to its average volume of 179,600. The stock has a market capitalization of $665.39 million, a P/E ratio of -5.51 and a beta of 1.71. Mineralys Therapeutics has a one year low of $5.85 and a one year high of $16.91. The stock’s fifty day moving average price is $12.95 and its 200-day moving average price is $12.64.

Insider Transactions at Mineralys Therapeutics

In related news, CEO Jon Congleton sold 15,271 shares of the company’s stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $13.52, for a total transaction of $206,463.92. Following the sale, the chief executive officer now directly owns 895,941 shares of the company’s stock, valued at approximately $12,113,122.32. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Mineralys Therapeutics news, CEO Jon Congleton sold 15,271 shares of the firm’s stock in a transaction on Friday, October 11th. The stock was sold at an average price of $13.52, for a total value of $206,463.92. Following the sale, the chief executive officer now directly owns 895,941 shares in the company, valued at approximately $12,113,122.32. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Adam Scott Levy sold 10,757 shares of the company’s stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $13.57, for a total transaction of $145,972.49. Following the completion of the transaction, the chief financial officer now owns 236,854 shares of the company’s stock, valued at approximately $3,214,108.78. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 51,510 shares of company stock valued at $735,431. Insiders own 33.24% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Mineralys Therapeutics in a research report on Tuesday.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.